Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology

Jaffer A. Ajani, Thomas A. D’Amico, David J. Bentrem, +38

Journal of the National Comprehensive Cancer Network

Gastrointestinal OncologyLocalized Gastric CancerMedicineCancer ManagementImmunology +12

Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology

Jaffer A. Ajani, Thomas A. D’Amico, David J. Bentrem, +35

Journal of the National Comprehensive Cancer Network

Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low–Expressing Advanced Breast Cancer: Results From a Phase Ib Study

Shanu Modi, Haeseong Park, Rashmi K. Murthy, +14

Journal of Clinical Oncology

Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer

Mary L. Disis, Matthew H. Taylor, Karen Kelly, +14

JAMA Oncology

Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study

Kenji Tamura, Junji Tsurutani, Shunji Takahashi, +14

The Lancet Oncology

Breast OncologyOncologyBreast CancerPharmacotherapyCancer Treatment +4

Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors

Junji Tsurutani, Hiroji Iwata, Ian E. Krop, +13

Cancer Discovery

Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study

Kohei Shitara, Hiroji Iwata, Shunji Takahashi, +12

The Lancet Oncology

OncologyGastrointestinal OncologyGastroenterologyPathologyCancer Treatment +3

Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial

Jonathan D. Schoenfeld, Anita Giobbie‐Hurder, Srinika Ranasinghe, +34

The Lancet Oncology

MedicinePrevious PdBronchial NeoplasmImmune Checkpoint InhibitorCancer Treatment +3

Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study

Eric Van Cutsem, Maria Di Bartolomeo, Elizabeth Smyth, +13

The Lancet Oncology

Disease ProgressionGastrointestinal OncologyMedicineGastroenterologyPathology +6

Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22–05): a single-arm, phase 1b–2 trial

Daniel V.T. Catenacci, Yoon‐Koo Kang, Haeseong Park, +31

The Lancet Oncology

OncologyEsophageal CancerGastrointestinal OncologyPathologyImmune Checkpoint Inhibitor +5